NASDAQ:IDXX - IDEXX Laboratories Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$248.14 +5.32 (+2.19 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$242.82
Today's Range$242.27 - $248.65
52-Week Range$146.09 - $248.65
Volume545,800 shs
Average Volume499,492 shs
Market Capitalization$20.77 billion
P/E Ratio74.77
Dividend YieldN/A
Beta0.68
IDEXX Laboratories logoIDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Debt-to-Equity Ratio-12.43
Current Ratio0.96
Quick Ratio0.72

Price-To-Earnings

Trailing P/E Ratio74.77
Forward P/E Ratio59.51
P/E Growth2.83

Sales & Book Value

Annual Sales$1.97 billion
Price / Sales10.95
Cash Flow$4.4896 per share
Price / Cash55.27
Book Value($0.62) per share
Price / Book-400.23

Profitability

EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Net Margins13.87%
Return on Equity-530.24%
Return on Assets19.39%

Miscellaneous

Employees7,600
Outstanding Shares86,860,000
Market Cap$20,768.99

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its Board of Directors has initiated a share buyback program on Sunday, June 4th 2017, which allows the company to buyback 3,000,000 outstanding shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Friday, May, 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.92 by $0.09. The company earned $537.60 million during the quarter, compared to the consensus estimate of $525.14 million. IDEXX Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. IDEXX Laboratories's quarterly revenue was up 16.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.77 earnings per share. View IDEXX Laboratories' Earnings History.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share (EPS) guidance of $4.06-4.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.11. The company issued revenue guidance of +12-14% to ~$2.205-2.245 billion, compared to the consensus revenue estimate of $2.22 billion.

What price target have analysts set for IDXX?

7 equities research analysts have issued 12-month target prices for IDEXX Laboratories' shares. Their forecasts range from $200.00 to $260.00. On average, they anticipate IDEXX Laboratories' stock price to reach $222.8333 in the next twelve months. This suggests that the stock has a possible downside of 10.2%. View Analyst Ratings for IDEXX Laboratories.

What is the consensus analysts' recommendation for IDEXX Laboratories?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 56)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 54)
  • Mr. Jay Mazelsky, Exec. VP (Age 57)

Has IDEXX Laboratories been receiving favorable news coverage?

Headlines about IDXX stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. IDEXX Laboratories earned a news impact score of 0.14 on Accern's scale. They also gave news coverage about the company an impact score of 45.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include American Capital Management Inc. (0.57%), Welch & Forbes LLC (0.21%), Davis R M Inc. (0.20%), Bank of Montreal Can (0.19%), Chicago Capital LLC (0.12%) and Franklin Street Advisors Inc. NC (0.06%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including American Capital Management Inc., Davis R M Inc., Hartford Investment Management Co., Calamos Advisors LLC, CenturyLink Investment Management Co, Welch & Forbes LLC, Spence Asset Management and Tokio Marine Asset Management Co. Ltd.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Westpac Banking Corp, Bank of Montreal Can, Franklin Street Advisors Inc. NC, First Citizens Bank & Trust Co., State of Alaska Department of Revenue, V Wealth Management LLC and NN Investment Partners Holdings N.V.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $248.14.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $20.77 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  341 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  548
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.